Contribution: Industrial Research Assistance Program – Contributions to Firms
Sanotize Research and Development Corp.
$5,500,000.00
COVID-19: NITRIC OXIDE NASAL SPRAY AS PREVENTION FOR COVID-19
FY 2021-22 · 2022-02-14
Summary
To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronavirus disease-19 (COVID-19) infection, reduction of the need for medical intervention resulting from COVID19; and assess tolerability of NONS in participants with COVID-19.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
710549726
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-02-14 | 2021-22 | $500,000.00 |
| 3 | 2022-02-14 | 2021-22 | $6,500,000.00 |
| 4 | 2022-02-14 | 2021-22 | $5,500,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -1,000,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de -1 000 000 dollars.
Agreement End Date
2024-03-31
Agreement Number
987525
Agreement Start Date
2022-02-14
Agreement Title
COVID-19: NITRIC OXIDE NASAL SPRAY AS PREVENTION FOR COVID-19
Agreement Title (French)
COVID-19 : VAPORISATEUR NASAL D'OXYDE NITRIQUE POUR LA PRÉVENTION DE LA COVID-19
Agreement Type
Contribution
Agreement Value
$5,500,000.00
Amendment Date
2023-11-20
Amendment Number
4
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronavirus disease-19 (COVID-19) infection, reduction of the need for medical intervention resulting from COVID19; and assess tolerability of NONS in participants with COVID-19.
Description (French)
Évaluer l'efficacité d'un vaporisateur nasal d'oxyde nitrique (VNON) afin de réduire le risque d'infection symptomatique par le coronavirus-19 (COVID-19), de réduire le besoin d'intervention médicale résultant de la COVID-19 et d'évaluer la tolérance du VNON chez les participants atteints de la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Granville
Federal Riding (French)
Vancouver Granville
Federal Riding Number
59036
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
710549726
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Sanotize Research and Development Corp.
Recipient Operating Name
SaNOtize
Recipient Postal Code
V6P 6T3
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2021-2022-Q4-987525
